Induction gemcitabine-based chemotherapy and neoadjuvant stereotactic body radiation therapy achieve high margin-negative resection rates for borderline resectable pancreatic cancer

详细信息    查看全文

• 作者：Michael D. Chuong (1)
  Gregory M. Springett (2)
  Jill Weber (2)
  Jason Klapman (2)
  Shivakumar Vignesh (2)
  Pamela J. Hodul (2)
  Mokenge P. Malafa (2)
  Susan Leuthold (1)
  Sarah E. Hoffe (1)
  Ravi Shridhar (1)
  
• 关键词：Stereotactic body radiation therapy ; Borderline resectable pancreatic cancer ; GTX
• 刊名：Journal of Radiation Oncology
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：1
• 期：3
• 页码：273-281
• 全文大小：306KB
• 参考文献：1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-00. doi:10.3322/caac.20073 dx.doi.org/10.3322/caac.20073">CrossRef
  2. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363(9414):1049-057. doi:10.1016/S0140-6736(04)15841-8 dx.doi.org/10.1016/S0140-6736(04)15841-8">CrossRef
  3. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13(8):1035-046. doi:10.1245/ASO.2006.08.011 dx.doi.org/10.1245/ASO.2006.08.011">CrossRef
  4. Abrams RA, Lowy AM, O’Reilly EM, Wolff RA, Picozzi VJ, Pisters PW (2009) Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 16(7):1751-756. doi:10.1245/s10434-009-0413-9 dx.doi.org/10.1245/s10434-009-0413-9">CrossRef
  5. Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, Prinz RA (1999) Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 65(7):618-23, discussion 623-14
  6. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234(6):758-68 dx.doi.org/10.1097/00000658-200112000-00007">CrossRef
  7. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-16 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567-79 dx.doi.org/10.1016/S1091-255X(00)80105-5">CrossRef
  8. Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G (2011) Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol 104(2):155-61. doi:10.1002/jso.21954 dx.doi.org/10.1002/jso.21954">CrossRef
  9. Mehta VK, Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Fisher GA (2001) Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 24(2):155-59 dx.doi.org/10.1097/00000421-200104000-00012">CrossRef
  10. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, Sgotto E, Gabriele P, Aglietta M (2006) Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 13(9):1201-208. doi:10.1245/s10434-006-9032-x dx.doi.org/10.1245/s10434-006-9032-x">CrossRef
  11. Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB, Bauer TW (2011) Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 18(3):619-27. doi:10.1245/s10434-010-1456-7 dx.doi.org/10.1245/s10434-010-1456-7">CrossRef
  12. Bockbrader M, Kim E (2009) Role of intensity-modulated radiation therapy in gastrointestinal cancer. Expert Rev Anticancer Ther 9(5):637-47. doi:10.1586/era.09.16 dx.doi.org/10.1586/era.09.16">CrossRef
  13. Poppe MM, Narra V, Yue NJ, Zhou J, Nelson C, Jabbour SK (2011) A comparison of helical intensity-modulated radiotherapy, intensity-modulated radiotherapy, and 3D-conformal radiation therapy for pancreatic cancer. Med Dosim 36(4):351-57. doi:10.1016/j.meddos.2010.08.003 dx.doi.org/10.1016/j.meddos.2010.08.003">CrossRef
  14. Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R, Hanna N, Regine WF (2011) Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 79(1):158-62. doi:10.1016/j.ijrobp.2009.10.043 dx.doi.org/10.1016/j.ijrobp.2009.10.043">CrossRef
  15. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD (2005) Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 63(4):1010-015. doi:10.1016/j.ijrobp.2005.03.073 dx.doi.org/10.1016/j.ijrobp.2005.03.073">CrossRef
  16. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7):1623-631. doi:10.1002/cncr.20539 dx.doi.org/10.1002/cncr.20539">CrossRef
  17. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27(10):1579-584. doi:10.1200/JCO.2008.19.6386 dx.doi.org/10.1200/JCO.2008.19.6386">CrossRef
  18. Scorsetti M, Mancosu P, Navarria P, Tozzi A, Castiglioni S, Clerici E, Reggiori G, Lobefalo F, Fogliata A, Cozzi L (2011) Stereotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of advanced techniques with modulated photons and protons. Strahlenther Onkol 187(4):238-44. doi:10.1007/s00066-011-2207-9 dx.doi.org/10.1007/s00066-011-2207-9">CrossRef
  19. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC (2009) Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115(3):665-72. doi:10.1002/cncr.24059 dx.doi.org/10.1002/cncr.24059">CrossRef
  20. Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA (2004) Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58(4):1017-021. doi:10.1016/j.ijrobp.2003.11.004 dx.doi.org/10.1016/j.ijrobp.2003.11.004">CrossRef
  21. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63(2):320-23. doi:10.1016/j.ijrobp.2005.07.002 dx.doi.org/10.1016/j.ijrobp.2005.07.002">CrossRef
  22. Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C (2010) Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 78(3):735-42. doi:10.1016/j.ijrobp.2009.08.046 dx.doi.org/10.1016/j.ijrobp.2009.08.046">CrossRef
  23. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M (2011) Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 81(4):e615–e622. doi:10.1016/j.ijrobp.2011.04.045 dx.doi.org/10.1016/j.ijrobp.2011.04.045">CrossRef
  24. Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G (2010) Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 17(8):2092-101. doi:10.1245/s10434-010-1019-y dx.doi.org/10.1245/s10434-010-1019-y">CrossRef
  25. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J (2008) The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Canc Chemother Pharmacol 61(1):167-75. doi:10.1007/s00280-007-0473-0 dx.doi.org/10.1007/s00280-007-0473-0">CrossRef
  26. Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, Malafa M (2008) PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 15(9):2465-471. doi:10.1245/s10434-008-9992-0 dx.doi.org/10.1245/s10434-008-9992-0">CrossRef
  27. Gastrointestinal Tumor Study Group (1979) Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Int J Radiat Oncol Biol Phys 5(9):1643-647 dx.doi.org/10.1016/0360-3016(79)90789-2">CrossRef
  28. Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Canc Inst 80(10):751-55 dx.doi.org/10.1093/jnci/80.10.751">CrossRef
  29. Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ (2004) Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 40(4):549-58. doi:10.1016/j.ejca.2003.10.026 dx.doi.org/10.1016/j.ejca.2003.10.026">CrossRef
  30. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL (2001) Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 5(2):121-30 dx.doi.org/10.1016/S1091-255X(01)80023-8">CrossRef
  31. Heinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, Clavien PA (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248(6):1014-022. doi:10.1097/SLA.0b013e318190a6da dx.doi.org/10.1097/SLA.0b013e318190a6da">CrossRef
  32. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR (2007) A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14(7):2088-096. doi:10.1245/s10434-007-9384-x dx.doi.org/10.1245/s10434-007-9384-x">CrossRef
  33. Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H (2005) Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76(1):48-3. doi:10.1016/j.radonc.2004.12.022 dx.doi.org/10.1016/j.radonc.2004.12.022">CrossRef
  34. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72(3):678-86. doi:10.1016/j.ijrobp.2008.01.051 dx.doi.org/10.1016/j.ijrobp.2008.01.051">CrossRef
  35. Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, Li T, Ciocca V, Cooper H, Hoffman JP (2008) Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 195(3):318-21. doi:10.1016/j.amjsurg.2007.12.017 dx.doi.org/10.1016/j.amjsurg.2007.12.017">CrossRef
  36. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB 3rd (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101(7):587-92. doi:10.1002/jso.21527 dx.doi.org/10.1002/jso.21527">CrossRef
  
• 作者单位：Michael D. Chuong (1)
  Gregory M. Springett (2)
  Jill Weber (2)
  Jason Klapman (2)
  Shivakumar Vignesh (2)
  Pamela J. Hodul (2)
  Mokenge P. Malafa (2)
  Susan Leuthold (1)
  Sarah E. Hoffe (1)
  Ravi Shridhar (1)
  
  1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA
  2. Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
  

文摘

Objectives Patients with borderline resectable pancreatic cancer (BRPC) have a higher probability of undergoing margin-negative resection after completing neoadjuvant therapy. Here, we describe a novel neoadjuvant approach using induction chemotherapy followed by stereotactic body radiation therapy (SBRT) for patients with BRPC. Methods This analysis included patients with nonmetastatic BRPC treated with neoadjuvant gemcitabine-based chemotherapy and five-fraction SBRT. Chemotherapy consisted of 3?cycles of Gemzar, Taxotere, and Xeloda. Patients were restaged to determine resectability, and nonmetastatic resectable patients underwent surgical resection. Results Thirty patients completed neoadjuvant treatment and were offered surgical exploration. Seventeen patients (56.7?%) reported no acute adverse effects during SBRT. No grade 3 or higher toxicity was observed from SBRT. Twenty-nine patients (96.7?%) underwent exploration. Twenty-one (95.6?%) of those who underwent pancreatic tumor resection achieved negative margins, with none requiring vessel resection. One (3.3?%) patient was resected with microscopic positive margins. Median follow-up was 15.6?months (range, 6.3-6.1?months). Median and 1-year overall survival was 20?months and 91?%, respectively. Median and 1-year progression-free survival was 14.9?months and 61?%, respectively. Conclusion SBRT-based neoadjuvant therapy for BRPC is well tolerated and can result in a high rate of margin-negative tumor resection.